Hyderabad, Oct 30 (UNI) Suven Life Sciences today announced that its revenue increased by ten per cent to Rs 58.89 crore for the six months ending September 2007 from Rs 53.59 crore in the corresponding period last year.
According to a company release here, the Profit After Tax (PAT) stood at Rs 4.31 crore compared to Rs 4.57 crore in the corresponding period.
The segmental revenue for the first six months from Drug Discovery Development Support Services (DDDSS) increased by 84 per cent to Rs 10.08 crore from Rs 5.48 crore.
However, there was reduction in Contract Research and Manufacturing Services (CRAMS) revenue for the six months from Rs 47.96 crore to Rs 46.46 crore by three per cent.
For the second quarter ending September 2007, the revenue increased by seven per cent to Rs 29.91 crore compared to the corresponding previous quarter of Rs 27.97 crore.
The PAT stood at Rs 1.16 crore compared to Rs 2.49 crore in the corresponding previous quarter.
Suven's major thrust on innovative R&D in Drug Discovery continued with a total expenditure of Rs 15.43 crore recording about 26 per cent of revenue for six months.